文献速递淋巴瘤

格菲妥单抗治疗复发/难治性B细胞淋巴瘤的疗效及影响因素分析

[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

单中心回顾性分析纳入32例在北京同仁医院接受格菲妥单抗治疗的复发/难治性B细胞淋巴瘤患者,中位随访414天,180天PFS率39.1%,OS率72.2%。挽救治疗可评估患者ORR 47.6%,CR率14.3%;桥接治疗6例均达部分缓解。单药治疗和多线治疗是PFS危险因素,CRS发生率28.1%,无≥3级CRS/ICANS。

要点

  • 格菲妥单抗在R/R B细胞淋巴瘤中ORR 47.6%,CR率14.3%,桥接治疗6例均达PR。
  • 单药治疗、多线治疗、既往CAR-T或苯达莫司汀是PFS危险因素。
  • CRS发生率28.1%,无≥3级CRS/ICANS,需加强监测和支持治疗。

核心结论

  • 格菲妥单抗在R/R B细胞淋巴瘤中展现良好潜力,但多线治疗患者单药疗效受限,联合方案更符合临床需求。

研究设计与样本

  • 单中心回顾性分析纳入北京同仁医院接受格菲妥单抗治疗的32例R/R B细胞淋巴瘤患者。
  • 研究终点为PFS、OS、ORR及安全性,采用单因素和多因素Cox回归筛选预后因素。

主要发现

  • 中位随访414天(95%CI:175~未达到),180天PFS率39.1%(95%CI:24.0%~63.7%),180天OS率72.2%(95%CI:57.5%~90.8%)。
  • 挽救治疗25例中21例可评估,ORR 47.6%,CR率14.3%;桥接治疗6例均达部分缓解。
  • 单因素分析显示治疗前线数(HR=1.55,95%CI:1.15~2.07,P=0.004)、既往CAR-T(HR=3.35,95%CI:1.07~10.49,P=0.038)、既往苯达莫司汀(HR=3.45,95%CI:1.05~11.41,P=0.042)和单药治疗(HR=4.18,95%CI:1.42~12.33,P=0.010)是PFS危险因素。
  • CRS发生率28.1%,1例合并ICANS,未出现≥3级CRS或ICANS。

临床怎么用

  • 格菲妥单抗可用于R/R B细胞淋巴瘤挽救治疗及桥接治疗,桥接治疗6例均达部分缓解。
  • 多线治疗或既往CAR-T、苯达莫司汀暴露患者单药疗效受限,可考虑联合方案。
  • 治疗中需监测CRS和ICANS,加强不良事件监测和支持治疗。

局限性

  • 单中心回顾性分析,样本量32例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This single-center retrospective analysis enrolled 32 patients with relapsed/refractory (R/R) B-cell lymphoma who received glofitamab-containing regimens at Beijing Tongren Hospital. Study endpoints were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Univariate and multivariate Cox regression analyses were conducted to identify prognostic factors. The median follow-up duration was 414 (95% CI: 175 - not reached) days, with a 180-day PFS rate of 39.1% (95% CI: 24.0%-63.7%) and a 180-day OS rate of 72.2% (95% CI: 57.5%-90.8%). The ORR was 47.6% and the complete response rate (CRR) was 14.3% in 21 evaluable patients among 25 patients who received glofitamab as salvage therapy. All 6 patients who received glofitamab as bridging therapy achieved a partial response. Univariate analysis revealed the number of prior treatment lines (HR=1.55, 95% CI: 1.15-2.07, P=0.004), prior CAR-T cell therapy (HR=3.35, 95% CI: 1.07-10.49, P=0.038), prior treatment with bendamustine (HR=3.45, 95% CI: 1.05-11.41, P=0.042), and glofitamab monotherapy (HR=4.18, 95% CI: 1.42-12.33, P=0.010) as risk factors for PFS. The incidence of cytokine release syndrome (CRS) was 28.1%, with one patient also developing immune effector cell-associated neurotoxicity syndrome (ICANS), and no grade of ≥3 CRS or ICANS was observed. Glofitamab demonstrates considerable potential in R/R B-cell lymphoma; however, its efficacy as monotherapy is limited in heavily pretreated patients. Combination regimens may better address clinical needs; however, enhanced monitoring for adverse events and supportive care are warranted. 单中心回顾性分析纳入于北京同仁医院接受格菲妥单抗治疗的32例复发/难治性(R/R)B细胞淋巴瘤患者,以无进展生存(PFS)、总生存(OS)、客观缓解率(ORR)及安全性为研究终点,单因素和多因素Cox回归筛选预后相关因素。中位随访时间为414(95% CI:175~未达到)d,180 d PFS率为39.1%(95% CI:24.0%~63.7%),180 d OS率为72.2%(95% CI:57.5%~90.8%)。格菲妥单抗作为挽救治疗(25例)时,21例可评估患者的ORR为47.6%,完全缓解(CR)率为14.3%。格菲妥单抗用于桥接治疗的6例患者均取得部分缓解。单因素分析结果显示治疗前线数(HR=1.55,95% CI:1.15~2.07,P=0.004)、治疗前接受CAR-T细胞治疗(HR=3.35,95% CI:1.07~10.49,P=0.038)、治疗前接受苯达莫司汀治疗(HR=3.45,95% CI:1.05~11.41,P=0.042)和格菲妥单抗单药治疗(HR=4.18,95% CI:1.42~12.33,P=0.010)是PFS的危险因素。细胞因子释放综合征(CRS)发生率为28.1%,1例患者合并免疫效应细胞相关神经毒性综合征(ICANS),未出现3级以上的CRS和ICANS。格菲妥单抗在R/R B细胞淋巴瘤中展现出了良好潜力,但在多线治疗的患者中单药疗效受限。联合方案更符合临床需求,但需加强不良事件监测和支持治疗。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Cong J, Wang CJ, Yao N, et al. [Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42409737. doi:10.3760/cma.j.cn121090-20260104-00002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。